Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jun 10;9(6):e99388.
doi: 10.1371/journal.pone.0099388. eCollection 2014.

Risk of lymphoma and solid cancer among patients with rheumatoid arthritis in a primary care setting

Affiliations

Risk of lymphoma and solid cancer among patients with rheumatoid arthritis in a primary care setting

Christen Lykkegaard Andersen et al. PLoS One. .

Abstract

Background: Several studies have demonstrated an association between rheumatoid arthritis (RA) and lymphoproliferative malignancies, but pathogenic mechanisms remain unclear. We investigated 1) the risk of lymphoproliferative malignancies and solid tumors in adults with RA identified in primary care and 2) the possible mediating role of blood eosinophilia in the clonal evolution of cancer in these patients.

Methods: From the Copenhagen Primary Care Differential Count (CopDiff) Database, we identified 356,196 individuals with at least one differential cell count (DIFF) encompassing the eosinophil count between 2000-2007. From these, one DIFF was randomly chosen (the index DIFF). By linking to the Danish National Patient Register, we categorized the selected individuals according to known longstanding (≥3 years) or recent onset (<3 years) RA prior to the index DIFF. In addition, the cohort was stratified according to management in primary or secondary care. From the Danish Cancer Registry we ascertained malignancies within four years following the index DIFF. Using multivariable logistic regression, odds ratios (OR) were calculated and adjusted for sex, age, year, month, eosinophilia, comorbid conditions and C-reactive protein (CRP).

Results: 921 patients had recent onset RA and 2,578 had longer disease duration. Seventy three percent of RA patients were managed in primary care. After adjustment for sex, age, year, and month, neither recent onset nor long-standing RA was associated with incident lymphoproliferative malignancies or solid cancers. These risk estimates did not change when eosinophilia, CRP, and comorbidities were included in the models.

Conclusions: In this large cohort of patients with RA of short or long duration recruited from a primary care resource, RA was not associated with an increased risk of lymphoproliferative or solid cancers during 4 years of follow-up, when the models were adjusted for confounders. Blood eosinophilia could not be identified as a mediator of cancer development in the present setting.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Flowchart for the study population.
CGPL, Copenhagen General Practitioners' Laboratory; CopDiff, Copenhagen Primary Care Differential Count Database; CRS, The Danish Civil Registration System; DIFF, differential cell count; GP, general practitioner.
Figure 2
Figure 2. Timeline for index DIFF selection.
Figure 3
Figure 3. Flowchart illustrating the background for analytical approaches.

References

    1. Hemminki K, Liu X, Forsti A, Ji J, Sundquist J, et al. (2013) Subsequent leukaemia in autoimmune disease patients. Br J Haematol 161: 677–687. - PubMed
    1. Chakravarty EF, Michaud K, Wolfe F (2005) Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 32: 2130–2135. - PubMed
    1. Khurana R, Wolf R, Berney S, Caldito G, Hayat S, et al. (2008) Risk of development of lung cancer is increased in patients with rheumatoid arthritis: a large case control study in US veterans. J Rheumatol 35: 1704–1708. - PubMed
    1. Mercer LK, Davies R, Galloway JB, Low A, Lunt M, et al. (2013) Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Rheumatology (Oxford) 52: 91–98. - PMC - PubMed
    1. Askling J (2007) Malignancy and rheumatoid arthritis. Curr Rheumatol Rep 9: 421–426. - PubMed

Publication types